

<b>Informazione Regolamentata n. 0472-8-2023</b>	<b>Data/Ora Ricezione 17 Febbraio 2023 09:09:28</b>	<b>Euronext Star Milan</b>
--	---	----------------------------

Societa' : BB BIOTECH

Identificativo : 172563

Informazione  
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : 1.1

Data/Ora Ricezione : 17 Febbraio 2023 09:09:28

Data/Ora Inizio : 17 Febbraio 2023 09:09:36

Diffusione presunta

Oggetto : BB Biotech AG publishes its 2022 annual  
report

*Testo del comunicato*

Vedi allegato.

**Ad hoc announcement pursuant to Art. 53 LR**

February 17, 2023

Annual report of BB Biotech AG as at December 31, 2022

**BB Biotech AG publishes its 2022 annual report**

BB Biotech AG published its annual report for fiscal year 2022 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech's positioning, the investment areas covered by its portfolio and the companies it is invested in.

The year 2022 saw volatile market conditions for global equity and bond markets, with substantial stepwise increases in central bank rates, led by the US Federal Reserve Bank. The biotech stocks showed a mixed performance. Large caps gained value throughout 2022, while some small and mid caps experienced significant corrections. For the full year, BB Biotech's total share return was -24.3% in CHF and -19.0% in EUR, substantially behind the portfolio performance of -11.0% in CHF, -6.7% in EUR and -12.1% in USD. The net loss for BB Biotech in 2022 was CHF 358 mn.

As already announced on January 20, 2023, BB Biotech will propose a dividend of CHF 2.85 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2022. This marks a continuation of the dividend policy of the previous years.

BB Biotech's annual report 2022 is available under [report.bbbiotech.ch/2022/en](https://report.bbbiotech.ch/2022/en) resp. [www.bbbiotech.com](https://www.bbbiotech.com)

**For further information:****Investor Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00  
Dr. Silvia Siegfried-Schanz, [ssc@bellevue.ch](mailto:ssc@bellevue.ch)  
Maria-Grazia Alderuccio, [mga@bellevue.ch](mailto:mga@bellevue.ch)  
Claude Mikkelsen, [cmi@bellevue.ch](mailto:cmi@bellevue.ch)

**Media Relations**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00  
Tanja Chicherio, [tch@bellevue.ch](mailto:tch@bellevue.ch)

TE Communications AG, Bleichstrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28  
Thomas Egger, [teg@te-communications.ch](mailto:teg@te-communications.ch)

[www.bbbiotech.com](https://www.bbbiotech.com)

**Company profile**

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

**Disclaimer**

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Fine Comunicato n.0472-8

Numero di Pagine: 4